This article by Anthony Zappa (PharmD MBA) provides an assessment of the proposed rules and their potential impact on covered entities.

The 340B drug discount program provides substantial savings to certain nonprofit healthcare providers and facilities. Recent proposed changes to program rules may result in significantly lower savings and more rigorous compliance oversight requirements. Covered entities must be aware of these changes and how they will impact program results.

To read full text, use this link.

Share this on Twitter: